Pentraxin 3 in patients with severe sepsis or shock: the ALBIOS trial

Abstract

Background-The long pentraxin PTX3 is a key component of the humoral arm of innate immunity related to sepsis severity and mortality. We evaluated the clinical and prognostic significance of circulating PTX3 in the largest cohort ever reported of patients with severe sepsis or septic shock.

Calcineurin inhibitors reduce NFAT-dependent expression of antifungal pentraxin-3 by human monocytes

“…Independently of the CN‐NFAT role, a therapeutic use for PTX‐3 has been suggested in the context of antifungal therapies . Furthermore strong research efforts have been made to validate the increased levels of PTX‐3 as a biomarker for severe sepsis and other chronic inflammatory disorders . These studies have identified PTX‐3 as a very important factor of innate responses.…”

A critical role of pentraxin 3 in severe sepsis and septic shock

“…As already performed in the past 3 years, the Council of the European Society of Clinical Investigation (ESCI) will award at the next Scientific Meeting in Barcelona (30 May‐1 June 2018) the best clinical research article published in the European Journal of Clinical Investigation (EJCI) from November 2016 to October 2017. In the final selection round, five clinical articles were selected based on their outstanding scientific value . Among those finalists, the article by Caironi and co‐workers obtained the highest consideration and was selected as the winner of the 2018 ESCI Award for the Best EJCI Basic Research Article …”

“…In the final selection round, five clinical articles were selected based on their outstanding scientific value . Among those finalists, the article by Caironi and co‐workers obtained the highest consideration and was selected as the winner of the 2018 ESCI Award for the Best EJCI Basic Research Article …”

“…This is a sub‐study from the Albumin Italian Outcome Sepsis, a large multicentre, open‐label, randomized, controlled clinical trial enrolling 1818 patients with severe sepsis or septic shock admitted to 100 Italian intensive care units (ICUs) . In 958 patients from this cohort, pentraxin 3 (PTX3) was measured at day 1, 2 and 7 after patient enrolment . In those patients, serum levels of PTX3 were associated with the degree of organ dysfunction as assessed by the Sequential Organ Failure Assessment Score.…”

“…Moreover, the entity of PTX3 reduction was demonstrated to predict 90‐day overall mortality. Despite a limited prognostic discrimination, the higher the PTX3 reduction, the lower the mortality risk …”